RecruitingPhase 3NCT04166409
Neurological
Neurofibromatosis Type 2
Also known as NF2, bilateral acoustic neurofibromatosis, MISME syndrome, NF2 merlin deficiency
Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 tumor suppressor gene encoding merlin (schwannomin), a cytoskeletal protein. The hallmark is bilateral vestibular schwannomas causing progressive hearing loss, tinnitus, and b
ORPHA:637 ↗Gene NF2Prevalence 1-9 per 100,000 (Orphanet)Onset Adolescent, AdultAutosomal dominant genetic
16
studies recruiting now
as of 7 Sept 2026
94
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
23 Feb 2022
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT02523014
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
RecruitingPhase 2NCT04374305
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
RecruitingNCT00598351
Natural History Study of Patients With Neurofibromatosis Type 2
RecruitingPhase 2NCT05253131
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 16 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Neurofibromatosis Type 2 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: NF Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Neurofibromatosis Type 2
Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 tumor suppressor gene encoding merlin (schwannomin), a cytoskeletal protein. The hallmark is bilateral vestibular schwannomas causing progressive hearing loss, tinnitus, and balance problems. Patients also develop meningiomas, ependymomas, and other schwannomas throughout the nervous system. Bevacizumab has shown benefit for vestibular schwannoma growth; FAK inhibitors and MEK inhibitors are in active trials.
Common clinical features
Bilateral vestibular schwannomasHearing loss and tinnitusBalance problemsMeningiomasSpinal ependymomasFacial nerve palsyCataracts
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Selumetinib Sulfate (Koselugo)
Phase 3Sirolimus (Fyarro)
Before you apply
Things trial teams commonly ask about for Neurofibromatosis Type 2. Not eligibility rules; those are set by each study.
- Tumor growth rate on serial MRI (typically requiring 2 scans 6 months apart) is a standard eligibility criterion
- Hearing assessment (audiogram and word recognition scores) at baseline is required — hearing preservation is a key trial endpoint
- Bevacizumab treatment history and response must be documented for anti-angiogenic and alternative therapy trials
- NF2 severity scale (Manchester) and Karnofsky performance status are used for trial stratification
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).